Apaziquone

Drug Profile

Apaziquone

Alternative Names: EO 9; EOquin; Neoquin; NOR 701; NSC 382456; Qapzola

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Spectrum Pharmaceuticals
  • Developer Handok Inc; Nippon Kayaku; Spectrum Pharmaceuticals
  • Class Aziridines; Cytostatic antibiotics; Indolequinones
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bladder cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bladder cancer

Most Recent Events

  • 08 Mar 2017 Spectrum Pharmaceuticals plans a phase III trial for Bladder cancer (Adjuvant therapy) in USA
  • 12 Dec 2016 Spectrum Pharmaceuticals terminates a phase III trial in Bladder cancer (non-invasive disease) in USA and Canada due to business reasons (NCT01410565)
  • 14 Sep 2016 The Oncologic Drugs Advisory Committee (ODAC) does not recommends approval of apaziquone for Bladder cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top